Meta AnalysisID 4368
肾细胞癌中琥珀酸脱氢酶(SDH)突变的系统评价
CRD42018087806
What is the exact importance of succinate dehydrogenase (SDH) mutations in renal cell carcinoma?
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 4368
- Evidence Id
- 12926
- Core Evidence Id
- 12926
- Source Meta Analysis Id
- 4334
- Herb2 Meta Analysis Id
- HBMA004334
- Crd Id
- CRD42018087806
- Title
- A systematic review of succinate dehydrogenase (SDH) mutations in renal cell carcinoma
- Review Question
- What is the exact importance of succinate dehydrogenase (SDH) mutations in renal cell carcinoma?
- Study Type Included
- Case-controls Cohort
- Condition Being Studied
- All patients who are diagnosed with renal cell carcinoma (kidney cancers).
- Participant
- Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport primary urine. RCC is the most common type of kidney cancer in adults, responsible for approximately 90–95% of cases.The body is remarkably good at hiding the symptoms and as a result people with RCC often have advanced disease by the time it is discovered. The initial symptoms of RCC often include blood in the urine (occurring in 40% of affected persons at the time they first seek medical attention), flank pain (40%), a mass in the abdomen or flank (25%), weight loss (33%), fever (20%), high blood pressure (20%), night sweats and generally feeling unwell. When RCC metastasises, it most commonly spreads to the lymph nodes, lungs, liver, adrenal glands, brain or bones. Immunotherapy and targeted therapy have improved the outlook for metastatic RCC
- Animal
- Human Disease Modelled
- Intervention
- All patients who are diagnosed with renal cell carcinoma (kidney cancers). The purpose of our investigation was to identify definite succinate dehydrogenase mutations in tumor tissue (fresh-frozen tissue, formalin-fixed paraffin-embedded [FFPE] samples, and plasma) from patients with renal cell carcinoma and normal sex- and age-matched controls. Normal controls were defined as normal adjacent tissue samples. For normal controls, samples were the same or similar tissue type as those collected from patients with renal cell carcinoma.
- Comparator Control
- Normal controls were defined as normal adjacent tissue samples. For normal controls, samples were the same or similar tissue type as those collected from patients with renal cell carcinoma.
- Main Outcome
- Detection of some succinate dehydrogenase genetic alteration.
- Outcome Measure
- Additional Outcome
- Not applicable.
- Study Method
- Epidemiologic, Systematic review
- Keyword
- Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Mutation; SDHD protein, human; Succinate Dehydrogenase
- Contact
- Fatemeh Khatami [email protected]
- Organisational Affiliation
- Chronic Disease Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences emri.tums.ac.ir
- Funding Source
- Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- Country
- Iran
- Review Stage
- Review Ongoing
- First Submission Date
- 2018-02-02
- Registration Date
- 2018-02-06
- Anticipated Start Date
- 2018-01-20
- Anticipated Completion Date
- 2018-07-20
- Title Cn
- 肾细胞癌中琥珀酸脱氢酶(SDH)突变的系统评价
- Title En
- A systematic review of succinate dehydrogenase (SDH) mutations in renal cell carcinoma
- Bilingual Status
- complete